

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior listings of claims in the application.

Claims 1-65 (Cancelled).

66. (New) An isolated antibody that specifically binds to a human interleukin-11 receptor (IL-11R) protein or a fragment thereof, wherein the human IL-11R protein consists of an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422;
- (c) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 365;
- (d) the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422;
- (e) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 422;
- (f) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 365;
- (g) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 359;
- (h) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 345; and
- (i) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 324.

67. (New) The antibody of claim 66, wherein said antibody is a neutralizing antibody.

68. (New) The antibody of claim 66, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

69. (New) The antibody of claim 66, wherein said antibody is a polyclonal antibody.
70. (New) The antibody of claim 66, wherein said antibody is a monoclonal antibody.
71. (New) A pharmaceutical composition comprising the antibody of claim 66 and a pharmaceutically acceptable carrier.
72. (New) An isolated antibody that specifically binds to a human interleukin-11 receptor (IL-11R) or a fragment thereof.
73. (New) The isolated antibody of claim 72, wherein the human IL-11R is a soluble, mature human IL-11R.
74. (New) The isolated antibody of claim 72, wherein said antibody is a neutralizing antibody.
75. (New) The antibody of claim 72, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.
76. (New) The antibody of claim 72, wherein said antibody is a polyclonal antibody.

77. (New) The antibody of claim 72, wherein said antibody is a monoclonal antibody.
78. (New) A pharmaceutical composition comprising the antibody of claim 72 and a pharmaceutically acceptable carrier.
79. (New) An isolated antibody obtained using as an immunogen a human interleukin-11 receptor (IL-11R) or a fragment thereof.
80. (New) The isolated antibody of claim 79, wherein the human IL-11R is a soluble, mature human IL-11R.
81. (New) The isolated antibody of claim 79, wherein the human IL-11R consists of an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:2;
 - (b) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422;
 - (c) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 365;
 - (d) the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422;
 - (e) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 422;
 - (f) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 365;
 - (g) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 359;
 - (h) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 345; and
 - (i) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 324.

82. (New) The isolated antibody of claim 79, wherein said antibody is a neutralizing antibody.

83. (New) The isolated antibody of claim 79, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

84. (New) The isolated antibody of claim 79, wherein said antibody is a polyclonal antibody.

85. (New) The isolated antibody of claim 79, wherein said antibody is a monoclonal antibody.

86. (New) A pharmaceutical composition comprising the antibody of claim 79 and a pharmaceutically acceptable carrier.

87. (New) The isolated antibody of claim 79, wherein said antibody is obtained using as an immunogen a protein with tyrosine residues replaced with sulfated tyrosine residues.

88. (New) The isolated antibody of claim 79, wherein said immunogen is conjugated to a hapten.

89. (New) The isolated antibody of claim 79, wherein said hapten is keyhole limpet hemocyanin (KLH).